gemcitabine has been researched along with digoxin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abrego, J; Asara, JM; Attri, KS; Augustine, JJ; Berim, L; Cantley, LC; Chaika, NV; Dai, B; Dasgupta, A; Fleming, JB; Gebregiworgis, T; Goode, GD; Grandgenett, PM; Grem, JL; Gunda, V; Hankins, JH; Hollingsworth, MA; Illies, AL; Kim, JW; King, RJ; Lazenby, AJ; Ly, QP; Lyssiotis, CA; Mashadova, O; Matés, JM; Mehla, K; Murthy, D; Oliveto, JM; Powers, R; Purohit, V; Sasson, AR; Serkova, NJ; Shukla, SK; Singh, PK; Vernucci, E; Weekes, C; Yu, F | 1 |
| Hu, R; Jin, C; Liu, Y; Wang, K; Wang, R; Yang, M; Yang, Y; Zhang, M; Zhou, Y | 1 |
1 review(s) available for gemcitabine and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for gemcitabine and digoxin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.
Topics: Carbon; Deoxycytidine; Digoxin; Drug Resistance, Neoplasm; Gemcitabine; Glucose; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mucin-1; Pancreatic Neoplasms; Pentose Phosphate Pathway; Prognosis; Pyrimidines; Signal Transduction | 2017 |
Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Digoxin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Profiling; Germ Cells; Humans; Mice; Models, Biological; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcriptome; Xenograft Model Antitumor Assays | 2019 |